Skip to main content
康乐卫士 logo

康乐卫士 — Investor Relations & Filings

Ticker · 920575 ISIN · CNE1000059W8 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 537 across all filing types
Latest filing 2026-01-12 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920575

About 康乐卫士

https://www.klws.com/

Beijing Health Guard Biotechnology Inc. is a clinical-stage biopharmaceutical company specializing in the research, development, and commercialization of innovative recombinant human vaccines. The company leverages advanced structural biology and protein engineering platforms to create a diverse pipeline of vaccine candidates. Its primary focus includes the development of high-valent human papillomavirus (HPV) vaccines, with its trivalent and nine-valent candidates in late-stage clinical trials. Additionally, the company is advancing candidates for respiratory syncytial virus (RSV), shingles, and other infectious diseases. By utilizing recombinant protein technology, Health Guard aims to provide high-quality, affordable immunization solutions to address significant unmet medical needs. Its technical expertise encompasses antigen design, high-throughput screening, and large-scale manufacturing processes.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于北京康乐卫士生物技术股份有限公司接受关联方担保暨关联交易事项的核查意见
Regulatory Filings Classification · 73% confidence The document is a due diligence review opinion (“核查意见”) issued by the sponsor (中信证券) on related‐party guarantees and transactions, prepared under regulatory rules for Beijing Stock Exchange listings. It contains no financial statements or earnings data, nor is it a mere report publication notice. It is a compliance/regulatory submission rather than an annual, interim report, or management statement. This matches the “Regulatory Filings” fallback category for general compliance and attestation documents. Accordingly, the correct classification is RNS.
2026-01-12 Chinese
股权质押的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the pledge of shares by the company's controlling shareholder and actual controller. It details the number of shares pledged, the pledge terms, the pledgees, and the impact on control of the company. There are no financial statements, no earnings data, no management discussion, or other report content. The document is a regulatory announcement about share pledging activity, which fits best under the category of Capital/Financing Update (CAP). The document length is short and focused solely on share pledge information, not a full report or a voting result or management change. Therefore, the classification is CAP with high confidence.
2026-01-12 Chinese
关于公司银行授信暨关联交易公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the company's bank credit facilities and related party transactions, including guarantees and pledges by controlling shareholders and related parties. It includes specifics about credit limits, guarantees, board and shareholder meeting approvals, and the impact of these transactions on the company. The document is not a financial report, audit, earnings release, or management discussion. It is a regulatory announcement about financing and related party guarantees. The document length is 3170 characters, which is relatively short but contains substantive information about financing and guarantees rather than just announcing a report publication. Therefore, it fits best under Capital/Financing Update (CAP).
2026-01-07 Chinese
关于子公司偿还银行贷款的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Beijing Kangle Weishi Biotechnology Co., Ltd. regarding the repayment of a bank loan by its subsidiary. It details the progress of loan repayment, references a previous announcement about overdue loan repayment and frozen bank accounts, and provides a risk warning to investors. The content is focused on financing activities related to bank loans and repayment status, not on financial results, management changes, or regulatory certifications. The document length is short (680 characters) and it is a standalone announcement about financing status, which fits the category of Capital/Financing Update (CAP).
2025-12-18 Chinese
关于公司未按期偿还银行贷款及部分银行账户被冻结的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Beijing Kangle Weishi Biotechnology Co., Ltd. regarding the company's failure to repay bank loans on time and the freezing of some bank accounts. It details the amounts involved, collateral, legal disputes, and the impact on the company’s operations and financial condition. The document is a formal disclosure of financial distress and related risks, but it does not contain financial statements, audit opinions, or detailed financial performance data. It is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a certification or a voting result announcement. It is a regulatory announcement about financial difficulties and legal matters affecting the company’s liquidity and operations. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory disclosures that do not fit other specific categories.
2025-12-17 Chinese
第五届董事会第十四次会议决议公告
Board/Management Information Classification · 100% confidence The document is an announcement of the resolutions passed at the 14th meeting of the 5th Board of Directors of Beijing Kangle Weishi Biotechnology Co., Ltd. It details the appointment of a new Chief Financial Officer, voting results, meeting attendance, and compliance with legal procedures. The content focuses on board decisions and management changes rather than financial results or reports. It is not a full annual or interim report, nor an earnings release or audit report. The document fits the category of Board/Management Information (MANG) as it announces changes in senior management and board decisions.
2025-12-17 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.